Fig. 2: Progression-free and overall survival. | Nature Communications

Fig. 2: Progression-free and overall survival.

From: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial

Fig. 2: Progression-free and overall survival.The alternative text for this image may have been generated using AI.

A Kaplan-Meier estimates of progression-free and overall survival in patients treated with mFOLFOX plus nivolumab/ipilimumab in parallel (Arm A/A1) versus patients treated sequential with mFOLFOX plus nivolumab/ipilimumab (Arm A2) versus patients treated with mFOLFOX alone (Arm B) versus patients treated with FLOT (Arm C). Source data are provided as a Source data file. B Kaplan-Meier estimates of progression-free and overall survival in patients treated with mFOLFOX plus nivolumab/ipilimumab in parallel (Arm A/A1) versus patients treated with mFOLFOX alone (Arm B). Source data are provided as a Source data file. C Kaplan-Meier estimates of progression-free and overall survival in patients treated with mFOLFOX plus nivolumab/ipilimumab in parallel (ArmA/A1) versus patients treated sequential with mFOLFOX plus nivolumab/ipilimumab (Arm A2). Source data are provided as a Source data file. D Kaplan-Meier estimates of progression-free and overall survival in patients treatedwith FLOT plus nivolumab (Arm C). Source data are provided as a Source data file.

Back to article page